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Abstract 
Informed and voluntary consent are important 
aspects that should be considered when conducting 
human research. The importance of this has come to 
the forefront particularly since the atrocities of 
World War II. Since, there have been numerous 
legal additions to safeguard research volunteers and 
ethical approval applications also incorporate this 
process. Consent is therefore one of the nuts and 
bolts of research methodology. 
This article looks at the informed consent 
process and at how this is obtained. It discusses 
how research informed consent varies from consent 
for a clinical procedure and looks at occasions when 
this important aspect can be waived.  
Main Text 
Informed and voluntary consent are important 
aspects to consider when conducting human 
research. The Nuremberg Code1, The Declaration of 
Helsinki16 and The Belmont Report17 all support 
this key aspect. 
The Nuremberg Code1 a set of 10 ethical 
principles, is laid out following the atrocities of 
World War II to protect fellow humans who take 
part in medical experimentation. The first principle 
of this code is about ‘voluntary consent’. The 
Nuremberg Code1 highlights that a person must 
have ‘legal capacity to give consent’. This not only 
spells out that an assessment of capacity is 
necessary but also has implications in studies 
involving children, adolescents and vulnerable 
adults. Capacity is a time and decision specific 
assessment of the person’s understanding, ability to 
retain, weigh and communicate the information and 
their decision. A capacity assessment is more 
complex in children as one must consider their level 
of psychological development, their understanding 
of the decision as well as the views of the parents.2 
Following the Gillick ruling, it must be noted that 
children, even under the age of 16, have the 
capacity to consent to treatment, even if their 
parents do not consent.3 Whilst this is used in 
medical care, in most circumstances Gillick 
competency is not extrapolated to medical 
research.4 
Another important aspect of The Nuremberg 
Code (1947)1 is that a person must have the ‘free 
power of choice’. This means that they are not to be 
constrained or coerced in any way to join the study. 
It expands on the meaning of obtaining informed 
consent - that is that a person must be given enough 
information to ensure that they can take ‘an 
understanding and enlightened decision’.1 This 
means that a person must know the nature of the 
clinical trial, expected length of time during which 
the research will be undertaken, the aims and 
objectives, the way in which the trial will be 
conducted, any adverse effects or risks as well as 
potential benefits and alternative 
therapies/treatment options to the one under 
investigation. All these aspects, form the basis of 
the Integrated Research Application System (IRAS) 
form. This is the form through which ethical 
approval is requested - and this must be obtained 
prior to the commencement of a clinical trial. 
Finally, The Nuremberg Code (1947)1 also 
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stipulates that the process of ascertaining informed 
consent is the role of the chief investigator and 
emphasises that this role cannot be delegated. 
 The Declaration of Helsinki,16 underwritten by 
the World Medical Association, further expands on 
The Nuremberg Code. It explains why human 
research is needed but emphasises that despite this, 
the person’s health must remain the priority.5 It 
acknowledges the patient’s right to withdraw from a 
study and this may occur at any stage of the clinical 
trial. The Declaration of Helsinki also mentions the 
concept of assent, whereby participants who are not 
able to give informed consent (and therefore need a 
third party to do so on their behalf - this may 
include children and people with learning disability, 
amongst others) should still agree to participate in 
the clinical trial/research.5 
The Belmont Report17 emphasises the 
principles of beneficence, justice and respect.6 
Within this, it describes the participant as 
‘autonomous’, meaning that they can choose 
whether they would like to be part of a trial or 
otherwise. This forms the crux of informed consent. 
Furthermore, it stipulates that people with 
diminished capacity should be given additional 
safeguards.  
Informed consent should include information 
on premature termination of a clinical trial and this 
should only occur for efficacy, safety or feasibility 
reasons.22 The informed consent process is usually 
evidenced with signed consent documentation. 
However, there are occasions when this may not be 
possible. This does not preclude that the person 
does not receive the necessary information to make 
the decision is given, but waivers the need for 
signed documentation. This may be necessary to 
safeguard the person if the research is about 
sensitive topics (such as domestic violence 
research) or in research whereby there is “no more 
than minimal risk of harm to subjects” 7 or when 
written consent is not usually required for such 
procedure. This usually encompasses telephone and 
web-based surveys.7 
This begs the question - can informed consent 
be waived? There are some instances where some 
or all aspects of informed consent can be waived.8 
The Common Rule in the United States9 identifies 4 
main occasions where this can be waived, that is: 
1. There is minimal risk;
2. The resulting waiver does not affect the rights
or well-being of the people involved in the
research; 
3. The waiver is needed for the practicality of the
research methodology;
4. Additional information is provided to the
people involved in the research after this is
carried out (where practical).
Minimal risk is basically day-to-day risk, that 
we all could face as we go about our daily living. 
These risks are so commonplace, that we don’t 
usually think about these.10 In research terms, 
educational/public health or routine care aspects are 
examples that would be included under this 
umbrella.8 When thinking about methodology, 
certain modalities of data collection, such as 
surveys or reviewing medical notes, can also be 
regarded as minimal risk.11  
On an aside, both healthy volunteers and 
patients may receive payments, incentives or 
expenses payments for their participation in the 
clinical trial. This should not be related to risk. All 
payment information should be given to the 
participants and included in the patient participation 
leaflet.23 The Health Research Authority (UK) has 
issued specific guidance around payment and 
incentives in relation to research.23 
The second aspect of when informed consent 
can be waived goes hand in hand with minimal risk. 
It relates to ensuring that the resultant waiver does 
not go against the laws of the state or affect the 
person’s health, finance or legal aspects.8 
Some research methodologies make obtaining 
informed consent difficult - such as studies 
involving cluster level interventions or with large 
cluster sizes.8 Another possibility whereby gaining 
informed consent may be tricky is if the information 
disclosed during this process were to cause a bias 
either to the outcomes of the research or cause 
selection bias.  
It is very important to treat the ‘research 
subjects’ as individuals and in a humane way. This 
therefore implies that even if approval is granted on 
the basis that informed consent is not possible, it is 
still important to make the information on the study 
available (e.g. through leaflets, website links) to the 
potential subjects.8 Consideration should be made to 
ensure that this information is explained in a way 
that the persons involved in the study understand. 
One of the functions of informed consent is to 
allow the people involved in the study (and those 
treated at a later stage – i.e. after the publication of 
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that study), to benefit from the study outcomes. 
This justifies their risk exposure for the benefit of 
the general population.8  
So far we have talked about informed consent 
as a whole, but we must also consider the timeliness 
of that consent, that is, whether this should be done 
before or after the randomisation process. Good 
practice is for informed consent to be sought early 
on in the study.8 During randomised control trials 
(RCTs) the earliest opportunity is before the 
randomisation process whereby information will be 
provided about the different arms of the study. 
Moreover information about the study and expected 
outcomes as a whole should also be given. It is of 
paramount importance that comprehensive, honest 
and accurate information is given.  
However, if randomisation has taken place 
prior to consent being sought, as can be the case in 
cluster randomised controlled studies (C-RCTs), 
then the information given can be tailored to the 
relevant arm that the person has been allocated to.8 
In this case, it is thought justifiable to mention the 
generic study interventions and aims but not to give 
specific details about the study and the other arms 
as this lessens the likelihood of bias.8 
In some C-RCTs obtaining informed consent 
prior to randomisation may be difficult12 and this 
can raise ethical controversies.13 Some researchers 
insist that if the C-RCTs are assessing routine care 
and are associated with minimal risk this may 
preclude the need for informed consent,14 and 
others state that not obtaining consent prior to 
randomisation is ethical so long as this is obtained 
prior to the start of the study and the data 
collection.8 The counter-argument to this is an 
ethical one, with some researchers insisting that the 
difficultly of obtaining informed consent in C-RCTs 
should be managed by improving the structure 
around obtaining informed consent.12 The 1991 
International Guidelines for Ethical Review of 
Epidemiological Studies state: 
“When it is not possible to request 
informed consent from every individual to 
be studied, the agreement of a 
representative of a community or group 
may be sought… Approval given by a 
community representative should be 
consistent with general ethical 
principles… A leader may express 
agreement on behalf of a community, but 
an individual’s refusal of personal 
participation is binding” (15: p. 225-226). 
In essence it is clear that the informed consent 
process is important. It ensures that participants 
have enough information and understanding to 
make a decision as to whether they want to enter a 
clinical study that is in line with their beliefs, values 
and culture. However as there are some exceptions 
when this can be waived, informed consent is not an 
absolute criterion. It remains however, a critical 
aspect that must be considered when conducting 
clinical studies.  
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